21 Boletín Hipertensión VOL 26. 2025 / 18 - 21 Hipertensión y síndrome de ovarios poliquísticos: Una relación compleja Conclusiones La HTA y el SOP mantienen una relación compleja, relación que es bidireccional, con alteraciones hormonales y metabólicas muy características del SOP que parecen conferir un riesgo aumentado de desarrollar HTA, especialmente en mujeres en edad reproductiva y en aquellas con obesidad. El hiperandrogenismo y la resistencia a la insulina emergen como mediadores claves en esta conexión, tomando protagonismo y afectando la función vascular y la regulación de la presión arterial a través de múltiples vías fisiopatológicas Si bien la modificación del estilo de vida constituye la piedra angular del manejo, las intervenciones farmacológicas dirigidas a corregir el hiperandrogenismo, la resistencia a la insulina y otros factores de riesgo metabólico son fundamentales para disminuir el riesgo cardiovascular que sabemos trae esta enfermedad. Una detección temprana, la evaluación detallada y el manejo integrado y multidisciplinario tanto del SOP como de la HTA son necesarios porque la suma de intervenciones permiten reducir la carga de morbilidad cardiovascular en estas pacientes. Como en todas las patologías, la investigación de los mecanismos fisiopatológicos involucrados, permitirán tener cada vez mejores estrategias para prevenir la progresión y complicaciones del SOP. Referencias 1. Wang J, Wu D, Guo H, Li M. Hyperandrogenemia and insulin resistance: The chief culprit of polycystic ovary syndrome. Life Sciences 2019;236:116940. 2. Amiri M, Ramezani Tehrani F, Behboudi-Gandevani S, Bidhendi-Yarandi R, Carmina E. Risk of hypertension in women with polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Reproductive Biology and Endocrinology 2020;18:23. 3. Dilliyappan S, Satish Kumar A, Venkatesalu S, Palaniyandi T, Baskar G, Sivaji A, et al. Polycystic ovary syndrome: Recent research and therapeutic advancements. Life Sciences 2024;359:123221. 4. Ollila MM, Kaikkonen K, Järvelin M-R, Huikuri HV, Tapanainen JS, Franks S, et al. Self-Reported Polycystic Ovary Syndrome Is Associated With Hypertension: A Northern Finland Birth Cohort 1966 Study. The Journal of Clinical Endocrinology & Metabolism 2019;104:1221-1231. 5. Lecke SB, Morsch DM, Spritzer PM. CYP19 gene expression in subcutaneous adipose tissue is associated with blood pressure in women with polycystic ovary syndrome. Steroids 2011;76:1383-1388. 6. Tang Z, Guan J, Mao J-h, Han L, Zhang J-j, Chen R, et al. Quantitative risk-benefit profiles of oral contraceptives, insulin sensitizers and antiandrogens for women with polycystic ovary syndrome: A model-based meta-analysis. European Journal of Pharmaceutical Sciences 2023;190:106577. 7. Samarasinghe SNS, Ostarijas E, Long MJ, Erridge S, Purkayastha S, Dimitriadis GK, et al. Impact of insulin sensitization on metabolic and fertility outcomes in women with polycystic ovary syndrome and overweight or obesity—A systematic review, meta-analysis, and meta-regression. Obesity Reviews 2024;25:e13744. 8. Domecq JP, Prutsky G, Mullan RJ, Sundaresh V, Wang AT, Erwin PJ, et al. Adverse Effects of the Common Treatments for Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. The Journal of Clinical Endocrinology & Metabolism 2013;98:4646-4654. 9. Van der Ham K, Louwers YV, Laven JSE. Cardiometabolic biomarkers in women with polycystic ovary syndrome. Fertility and Sterility 2022;117:887-896. 10. Shao S, Xu Q, Zi Y, Zheng X, Chen S, Qin C, et al. The genetic association between polycystic ovary syndrome and the risk of hypertensive disorders of pregnancy: A Mendelian randomization study. European Journal of Obstetrics & Gynecology and Reproductive Biology 2025;305:351-355. 11. Juhász AE, Stubnya MP, Teutsch B, Gede N, Hegyi P, Nyirády P, et al. Ranking the dietary interventions by their effectiveness in the management of polycystic ovary syndrome: a systematic review and network meta-analysis. Reproductive Health 2024;21:28. 12. Heidarpour M, Mojarad M, Mazaheri-Tehrani S, Kachuei A, Najimi A, Shafe D, et al. Comparative Effectiveness of Antidiabetic Drugs as an Additional Therapy to Metformin in Women with Polycystic Ovary Syndrome: A Systematic Review of Metabolic Approaches. International Journal of Endocrinology 2024;2024:9900213. 13. Practice Committee of the American Society for Reproductive Medicine. Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. Fertility and Sterility 2017;108:426-441. 14. Practice Committee of the American Society for Reproductive Medicine. Use of insulin sensitizing agents in the treatment of polycystic ovary syndrome. Fertility and Sterility 2006;86:S13-S19. 15. Berbrier DE, Coovadia Y, Malenda D, Usselman CW. Polycystic ovary syndrome potentiates blood pressure and vascular responses to the cold pressor test. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2024;326:R228-R239. 16. Joham AE, Kakoly NS, Teede HJ, Earnest A. Incidence and Predictors of Hypertension in a Cohort of Australian Women With and Without Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism 2021;106:15851593. 17. Azziz R. Polycystic Ovary Syndrome. Obstetrics & Gynecology 2018;132:321-336. 18. Juhász AE, Stubnya MP, Teutsch B, Gede N, Hegyi P, Ács N, et al. Comparative efficacy of exercise, diet and/or pharmacological interventions on BMI, ovulation, and hormonal profile in reproductive-aged women with overweight or obesity: a systematic review and network meta-analysis. Human Reproduction Update 2024;30:472-487. 19. Treister-Goltzman Y, Nemet D, Menashe I. Associations of adolescent obesity with hypertension, diabetes mellitus and polycystic ovaries in Arabs and Jews in Israel—a nationwide study. Frontiers in Public Health 2024;12:1443756. 20. Cignarella A, Mioni R, Sabbadin C, Dassie F, Parolin M, Vettor R, et al. Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS. International Journal of Molecular Sciences 2020;21:9554.
RkJQdWJsaXNoZXIy MTYwMjk1